US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Propanc Biopharma, Inc.

0.4940

-0.0183-3.57%

Post-market: 0.4925-0.0015-0.30%19:38 EDT

Volume:134.49K

Turnover:67.94K

Market Cap:3.13M

PE:-0.03

High:0.5215

Open:0.5160

Low:0.4714

Close:0.5123

52wk High:52.50

52wk Low:0.4714

Shares:6.33M

Float Shares:1.25M

Volume Ratio:0.50

T/O Rate:10.76%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-17.6157

EPS(LYR):-371.2241

ROE:-161.86%

ROA:-70.14%

PB:0.33

PE(LYR):0.00

Loading ...

Overview Company News Filings

Propanc Biopharma Q4 EPS $(0.10)

Benzinga Earnings

Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results

THOMSON REUTERS

Propanc Biopharma Targets February 2027 First-Patient Dosing for Phase 1b PRP Cancer Trial

Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015

Propanc Biopharma - to Initiate Phase 1B Prp Study in February 2027 for up to 50 Patients

THOMSON REUTERS

Propanc Biopharma - Issues Comparative Analysis of Prp vs Daraxonrasib and Eras-0015

THOMSON REUTERS

Propanc Biopharma Plans Phase 1b First-in-Human PRP Trial in Advanced Solid Tumors Starting February 2027

Propanc Biopharma to Initiate World-First Phase 1B First-in-Human Study of Prp in February 2027

THOMSON REUTERS

Propanc Biopharma Plans First-in-Human Phase 1b PRP Trial Start in February 2027

Propanc Biopharma announces new preclinical data for PRP in PDAC

Propanc Biopharma Says PRP Cuts Pancreatic Tumor Growth by over 90% in Preclinical Models

Propanc Biopharma - Plans Phase 1B Study in 40–45 Patients with Advanced Solid Tumors, Clinical Trial Application Expected in Coming Months

THOMSON REUTERS

Propanc Biopharma - Prp Reduces Metastatic Burden in Liver and Peritoneum in Preclinical Models

THOMSON REUTERS

Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for Prp Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit

THOMSON REUTERS

Propanc Biopharma Issues 3.5 Million Restricted Shares to Executives, Directors, Service Providers

Propanc Biopharma starts finalization of clinical trial protocol for PRP study

Propanc Biopharma Plans First-in-Human Phase 1b Trial of PRP in up to 40 Advanced Solid Tumor Patients

Propanc Biopharma Plans Phase 1b Study of PRP Proenzyme Therapy in Advanced Solid Tumors

Propanc Biopharma - to File Phase 1B Clinical Trial Application for Prp in Advanced Cancer in Q4

THOMSON REUTERS

Propanc reports new preclinical data for PRP in pancreatic ductal adenocarcinoma

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/PPCB/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PPCB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPCB\",,,,,undefined,":{"symbol":"PPCB","market":"US","secType":"STK","nameCN":"Propanc Biopharma, Inc.","latestPrice":0.494,"timestamp":1790798400000,"preClose":0.5123,"halted":0,"volume":134486,"hourTrading":{"tag":"盘后","latestPrice":0.4925,"preClose":0.494,"latestTime":"19:38 EDT","volume":11426,"amount":5783.7892,"timestamp":1790811518263,"change":-0.0015,"changeRate":-0.003036,"amplitude":0.055668},"delay":0,"changeRate":-0.03572125707593204,"floatShares":1250100,"shares":6331100,"eps":-17.61573,"marketStatus":"Not Yet Opened","change":-0.0183,"latestTime":"09-30 16:00:00 EDT","open":0.516,"high":0.5215,"low":0.4714,"amount":67939.5164426,"amplitude":0.097794,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-17.61573,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1790841600000},"marketStatusCode":0,"adr":0,"listingDate":1743998400000,"exchange":"NASDAQ","adjPreClose":0.5123,"preHourTrading":{"tag":"盘前","latestPrice":0.5293,"preClose":0.5123,"latestTime":"09:25 EDT","volume":3190,"amount":1694.1149907000001,"timestamp":1790774751613,"change":0.017,"changeRate":0.033184,"amplitude":0.041772},"postHourTrading":{"tag":"盘后","latestPrice":0.4925,"preClose":0.494,"latestTime":"19:38 EDT","volume":11426,"amount":5783.7892,"timestamp":1790811518263,"change":-0.0015,"changeRate":-0.003036,"amplitude":0.055668},"volumeRatio":0.502252},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPCB\",,,,,undefined,":{"symbol":"PPCB","floatShares":1250100,"roa":"-70.14%","roe":"-161.86%","lyrEps":-371.224075,"volumeRatio":0.502252,"shares":6331100,"dividePrice":0,"high":0.5215,"amplitude":0.097794,"preClose":0.5123,"low":0.4714,"week52Low":0.4714,"pbRate":"0.33","week52High":52.5,"institutionHeld":0,"latestPrice":0.494,"eps":-17.61573,"divideRate":0,"volume":134486,"delay":0,"ttmEps":-17.61573,"open":0.516,"prevYearClose":13.415,"prevWeekClose":0.6303,"prevMonthClose":1.35,"prevQuarterClose":1.5,"fiveDayClose":0.628,"twentyDayClose":1.13,"sixtyDayClose":1.82},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PPCB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-18","symbol":"PPCB","defaultRemindTime":1779111000000,"type":"split","dateTimestamp":1779076800000,"forFactor":25,"toFactor":1,"ratio":25},{"market":"US","date":"2025-01-29","symbol":"PPCB","defaultRemindTime":1738161000000,"type":"split","dateTimestamp":1738126800000,"forFactor":60000,"toFactor":1,"ratio":60000},{"market":"US","date":"2023-05-23","symbol":"PPCB","defaultRemindTime":1684848600000,"type":"split","dateTimestamp":1684814400000,"forFactor":1000,"toFactor":1,"ratio":1000},{"market":"US","date":"2020-11-19","symbol":"PPCB","defaultRemindTime":1605796200000,"type":"split","dateTimestamp":1605762000000,"forFactor":1000,"toFactor":1,"ratio":1000},{"market":"US","date":"2019-06-24","symbol":"PPCB","type":"split","dateTimestamp":1561348800000,"forFactor":500,"toFactor":1,"ratio":500}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PPCB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PPCB\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PPCB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PPCB","date":"2026-09-29","current":-0.028043,"percent":0.286219,"low":-1.336323,"twenty":-0.249948,"median":-0.123469,"eighty":-0.042524,"high":-0.023125,"avg":-0.178049,"sd":0.187809,"marketCap":3377017},"quantilePoints":[{"date":"2025-04-04","current":-0.050633,"twenty":-0.050633,"median":-0.050633,"eighty":-0.050633,"marketCap":84546},{"date":"2025-04-07","current":-0.048332,"twenty":-0.050633,"median":-0.050633,"eighty":-0.049713,"marketCap":80703},{"date":"2025-08-22","current":-0.938461,"twenty":-0.969897,"median":-0.655598,"eighty":-0.050633,"marketCap":51812834},{"date":"2025-08-29","current":-0.721182,"twenty":-0.884372,"median":-0.710781,"eighty":-0.050633,"marketCap":39816759},{"date":"2025-09-05","current":-0.457673,"twenty":-0.820575,"median":-0.688821,"eighty":-0.213449,"marketCap":25268328},{"date":"2025-09-12","current":-0.457673,"twenty":-0.778969,"median":-0.631034,"eighty":-0.41283,"marketCap":25268328},{"date":"2025-09-19","current":-0.506214,"twenty":-0.755854,"median":-0.517772,"eighty":-0.439644,"marketCap":27948302},{"date":"2025-09-26","current":-0.418378,"twenty":-0.712861,"median":-0.510837,"eighty":-0.435021,"marketCap":23098825},{"date":"2025-10-03","current":-0.399917,"twenty":-0.699454,"median":-0.498124,"eighty":-0.407301,"marketCap":23564414},{"date":"2025-10-10","current":-0.408611,"twenty":-0.69067,"median":-0.457673,"eighty":-0.403395,"marketCap":24076684},{"date":"2025-10-17","current":-0.343407,"twenty":-0.669984,"median":-0.449583,"eighty":-0.385572,"marketCap":20234660},{"date":"2025-10-24","current":-0.321672,"twenty":-0.645772,"median":-0.432247,"eighty":-0.369488,"marketCap":18953985},{"date":"2025-10-31","current":-0.269509,"twenty":-0.610693,"median":-0.4245,"eighty":-0.343407,"marketCap":15880366},{"date":"2025-11-07","current":-0.241906,"twenty":-0.556142,"median":-0.418378,"eighty":-0.313847,"marketCap":14253909},{"date":"2025-11-14","current":-0.169965,"twenty":-0.518234,"median":-0.404264,"eighty":-0.269509,"marketCap":10014876},{"date":"2025-11-21","current":-0.174454,"twenty":-0.514536,"median":-0.397743,"eighty":-0.234995,"marketCap":11061584},{"date":"2025-11-28","current":-0.188344,"twenty":-0.512687,"median":-0.384703,"eighty":-0.189884,"marketCap":11942288},{"date":"2025-12-05","current":-0.173885,"twenty":-0.509912,"median":-0.372748,"eighty":-0.182127,"marketCap":11025501},{"date":"2025-12-12","current":-0.170028,"twenty":-0.504827,"median":-0.356448,"eighty":-0.174606,"marketCap":10780935},{"date":"2025-12-19","current":-0.151754,"twenty":-0.498818,"median":-0.343407,"eighty":-0.171335,"marketCap":9622255},{"date":"2025-12-26","current":-0.139108,"twenty":-0.496968,"median":-0.326019,"eighty":-0.170682,"marketCap":8820401},{"date":"2026-01-02","current":-0.113099,"twenty":-0.476627,"median":-0.315152,"eighty":-0.168873,"marketCap":7171266},{"date":"2026-01-09","current":-0.101254,"twenty":-0.460447,"median":-0.284723,"eighty":-0.163023,"marketCap":6420182},{"date":"2026-01-16","current":-0.074044,"twenty":-0.457673,"median":-0.262988,"eighty":-0.151375,"marketCap":4694858},{"date":"2026-01-23","current":-0.056065,"twenty":-0.453513,"median":-0.243754,"eighty":-0.138341,"marketCap":3554888},{"date":"2026-01-30","current":-0.058573,"twenty":-0.449352,"median":-0.223866,"eighty":-0.121547,"marketCap":3713923},{"date":"2026-02-06","current":-0.042554,"twenty":-0.442879,"median":-0.192195,"eighty":-0.107345,"marketCap":2698240},{"date":"2026-02-13","current":-0.048688,"twenty":-0.435021,"median":-0.182701,"eighty":-0.093848,"marketCap":3087140},{"date":"2026-02-20","current":-0.048657,"twenty":-0.431486,"median":-0.176899,"eighty":-0.077306,"marketCap":3214676},{"date":"2026-02-27","current":-0.046857,"twenty":-0.428606,"median":-0.174834,"eighty":-0.060466,"marketCap":3095731},{"date":"2026-03-06","current":-0.040376,"twenty":-0.424799,"median":-0.173681,"eighty":-0.05647,"marketCap":2667530},{"date":"2026-03-13","current":-0.029045,"twenty":-0.422077,"median":-0.17085,"eighty":-0.050499,"marketCap":1918972},{"date":"2026-03-20","current":-0.028085,"twenty":-0.419765,"median":-0.170682,"eighty":-0.048484,"marketCap":1855535},{"date":"2026-03-27","current":-0.034166,"twenty":-0.417079,"median":-0.169454,"eighty":-0.047319,"marketCap":2257270},{"date":"2026-04-02","current":-0.035336,"twenty":-0.413827,"median":-0.167383,"eighty":-0.04606,"marketCap":2334602},{"date":"2026-04-10","current":-0.031762,"twenty":-0.406872,"median":-0.16427,"eighty":-0.043866,"marketCap":2098425},{"date":"2026-04-17","current":-0.033628,"twenty":-0.399911,"median":-0.155654,"eighty":-0.041322,"marketCap":2221738},{"date":"2026-04-24","current":-0.036697,"twenty":-0.399457,"median":-0.149858,"eighty":-0.040438,"marketCap":2424475},{"date":"2026-05-01","current":-0.032141,"twenty":-0.39557,"median":-0.138149,"eighty":-0.039889,"marketCap":2123505},{"date":"2026-05-08","current":-0.029421,"twenty":-0.386441,"median":-0.123469,"eighty":-0.037064,"marketCap":1943760},{"date":"2026-05-15","current":-0.023125,"twenty":-0.382964,"median":-0.117367,"eighty":-0.035899,"marketCap":1527837},{"date":"2026-05-22","current":-0.078772,"twenty":-0.376009,"median":-0.107725,"eighty":-0.036443,"marketCap":1446323},{"date":"2026-05-29","current":-0.077406,"twenty":-0.376009,"median":-0.101254,"eighty":-0.036697,"marketCap":1421242},{"date":"2026-06-05","current":-0.075584,"twenty":-0.369488,"median":-0.094421,"eighty":-0.037013,"marketCap":1387801},{"date":"2026-06-12","current":-0.110645,"twenty":-0.369488,"median":-0.091369,"eighty":-0.037013,"marketCap":2031540},{"date":"2026-06-18","current":-0.077861,"twenty":-0.359056,"median":-0.091369,"eighty":-0.037215,"marketCap":1429602},{"date":"2026-06-26","current":-0.068755,"twenty":-0.347754,"median":-0.088611,"eighty":-0.037494,"marketCap":1262397},{"date":"2026-07-02","current":-0.178687,"twenty":-0.344276,"median":-0.088611,"eighty":-0.038576,"marketCap":3280854},{"date":"2026-07-10","current":-0.220877,"twenty":-0.343407,"median":-0.091369,"eighty":-0.03962,"marketCap":4055500},{"date":"2026-07-17","current":-0.1973,"twenty":-0.335582,"median":-0.096459,"eighty":-0.039946,"marketCap":3622609},{"date":"2026-07-24","current":-0.179928,"twenty":-0.32515,"median":-0.101254,"eighty":-0.040156,"marketCap":3303637},{"date":"2026-07-31","current":-0.129051,"twenty":-0.321672,"median":-0.106776,"eighty":-0.040305,"marketCap":2369505},{"date":"2026-08-07","current":-0.16876,"twenty":-0.316456,"median":-0.111872,"eighty":-0.040388,"marketCap":3098584},{"date":"2026-08-14","current":-0.151387,"twenty":-0.306023,"median":-0.120497,"eighty":-0.04047,"marketCap":2779612},{"date":"2026-08-21","current":-0.136497,"twenty":-0.295156,"median":-0.123158,"eighty":-0.040781,"marketCap":2506208},{"date":"2026-08-28","current":-0.276716,"twenty":-0.28152,"median":-0.125329,"eighty":-0.041146,"marketCap":5080767},{"date":"2026-09-04","current":-0.12657,"twenty":-0.273833,"median":-0.12719,"eighty":-0.041245,"marketCap":2323938},{"date":"2026-09-11","current":-0.11699,"twenty":-0.269509,"median":-0.12657,"eighty":-0.041322,"marketCap":2148048},{"date":"2026-09-18","current":-0.078175,"twenty":-0.266901,"median":-0.125329,"eighty":-0.041661,"marketCap":1435373},{"date":"2026-09-25","current":-0.074676,"twenty":-0.254295,"median":-0.123158,"eighty":-0.042494,"marketCap":1371123},{"date":"2026-09-29","current":-0.179031,"twenty":-0.249948,"median":-0.123469,"eighty":-0.042524,"marketCap":3377017}],"updateTime":1790833129119},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PPCB\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2671108472","title":"Propanc Biopharma Q4 EPS $(0.10)","url":"https://stock-news.laohu8.com/highlight/detail?id=2671108472","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671108472?lang=en_us&edition=fundamental","pubTime":"2026-09-29 21:46","pubTimestamp":1790689603,"startTime":"0","endTime":"0","summary":"Propanc Biopharma (NASDAQ:PPCB) reported quarterly losses of $(0.10) per share.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/09/62049910/propanc-biopharma-q4-eps-0-10","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671145912","title":"Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2671145912","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671145912?lang=en_us&edition=fundamental","pubTime":"2026-09-29 20:30","pubTimestamp":1790685002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nTUAYVBP1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669487144","title":"Propanc Biopharma Targets February 2027 First-Patient Dosing for Phase 1b PRP Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669487144","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669487144?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:33","pubTimestamp":1790080407,"startTime":"0","endTime":"0","summary":"Propanc Biopharma targets February 2027 first-patient dosing for Phase 1b PRP cancer trialPropanc outlined new preclinical pancreatic cancer results for PRP, already presented in a newly released data","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL1Yqp8K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","PPCB","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","IE00BQXX3D17.EUR","SG9999014021.USD","LU2095319765.USD","LU2210149790.SGD","SG9999014013.SGD","BK4585","BCDF","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","IE00B64PRP62.GBP","IE00BQXX3C00.GBP","IE00BQXX3F31.USD","BK4139","LU2210150020.SGD","IE00BN0W2T93.GBP","BK4112","LU0314104364.USD","IE00BGHQF748.EUR","BK4588","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669144047","title":"Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015","url":"https://stock-news.laohu8.com/highlight/detail?id=2669144047","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669144047?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:30","pubTimestamp":1790080200,"startTime":"0","endTime":"0","summary":"New Preclinical PDAC Package for PRP Shows >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Contrasts Mechanism, Breadth, & Development Role Against Erasca’s Phase 1 ERAS-0015 Datase","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/22/3366329/0/en/propanc-biopharma-highlights-differentiated-prp-pancreatic-cancer-data-versus-emerging-pan-ras-program-eras-0015.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","IE00BYTNYN87.SGD","LU1023057109.AUD","BK4548","LU1720051017.SGD","PDX","LU1861220033.SGD","BK4605","BK4531","LU2360107325.USD","BK4141","SG9999011746.SGD","BK4588","BK4512","IE00B12V2V27.USD","LU0320765992.SGD","LU0724618433.USD","LU2298322129.HKD","BK4585","LU0509642566.USD","IE0002141913.USD","IDNA","ONG","ERAS","LU0109394709.USD","IE00BYQNZ168.SGD","TME","LU1548497426.USD","PPCB","BK4571","LU2357305700.SGD","RVMD","BK4535","ON","BK4108","LU1854103824.USD","IE0009354923.USD","LU1854104046.USD","LU0359202008.SGD","CANC","LU0269904917.USD","ONX","LU1861219969.SGD","BK4139","01698","PTH","BK4509","BK4565","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667983739","title":"Propanc Biopharma - to Initiate Phase 1B Prp Study in February 2027 for up to 50 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2667983739","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667983739?lang=en_us&edition=fundamental","pubTime":"2026-09-16 20:37","pubTimestamp":1789562255,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nFWN4580E1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667983732","title":"Propanc Biopharma - Issues Comparative Analysis of Prp vs Daraxonrasib and Eras-0015","url":"https://stock-news.laohu8.com/highlight/detail?id=2667983732","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667983732?lang=en_us&edition=fundamental","pubTime":"2026-09-16 20:37","pubTimestamp":1789562255,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nFWN4580E1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667983268","title":"Propanc Biopharma Plans Phase 1b First-in-Human PRP Trial in Advanced Solid Tumors Starting February 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2667983268","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667983268?lang=en_us&edition=fundamental","pubTime":"2026-09-16 20:33","pubTimestamp":1789561986,"startTime":"0","endTime":"0","summary":"Propanc Biopharma plans Phase 1b first-in-human PRP trial in advanced solid tumors starting February 2027Propanc Biopharma outlined plans to start a first-in-human Phase 1b study of PRP in February 20","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDL3BZyGM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BQXX3C00.GBP","IE00BN0W2V16.EUR","BCDF","NDAQ","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","IE00BKPKM429.USD","BK4585","BK4139","IE00BQXX3F31.USD","SG9999014021.USD","LU2095319765.USD","IE00BQXX3D17.EUR","SG9999014013.SGD","IE00BN0W2W23.USD","LU0314104364.USD","LU2210149790.SGD","BK4112","BK4588","IE00B3QW5Z07.USD","SG9999014005.SGD","SG9999014039.USD","PPCB","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666335565","title":"Propanc Biopharma to Initiate World-First Phase 1B First-in-Human Study of Prp in February 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2666335565","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666335565?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:33","pubTimestamp":1788957231,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nFWN4510KX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666353353","title":"Propanc Biopharma Plans First-in-Human Phase 1b PRP Trial Start in February 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2666353353","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666353353?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:32","pubTimestamp":1788957148,"startTime":"0","endTime":"0","summary":"Propanc Biopharma plans first-in-human Phase 1b PRP trial start in February 2027Propanc Biopharma plans to start a Phase 1b first-in-human study of PRP in February 2027 in Australia.No clinical result","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDLbVXWJ2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4112","IE00BQXX3C00.GBP","SG9999014039.USD","IE00BKPKM429.USD","SG9999014021.USD","IE00B64PRP62.GBP","NDAQ","SG9999014005.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","BK4585","SG9999014013.SGD","IE00BQXX3F31.USD","IE00BN0W2V16.EUR","BK4588","BCDF","LU0314104364.USD","IE00BN0W2T93.GBP","LU2210149790.SGD","IE00B3QW5Z07.USD","BK4139","IE00BQXX3D17.EUR","LU2095319765.USD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662700133","title":"Propanc Biopharma announces new preclinical data for PRP in PDAC","url":"https://stock-news.laohu8.com/highlight/detail?id=2662700133","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662700133?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:45","pubTimestamp":1787834733,"startTime":"0","endTime":"0","summary":"Propanc Biopharma (PPCB) announced new preclinical and early translational data for PRP in pancreatic ductal adenocarcinoma, or PDAC. In orthotopic...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-announces-new-preclinical-data-for-prp-in-pdac-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-announces-new-preclinical-data-for-prp-in-pdac-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662707660","title":"Propanc Biopharma Says PRP Cuts Pancreatic Tumor Growth by over 90% in Preclinical Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2662707660","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662707660?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:30","pubTimestamp":1787833847,"startTime":"0","endTime":"0","summary":"Propanc Biopharma says PRP cuts pancreatic tumor growth by over 90% in preclinical modelsPropanc reported new preclinical PDAC data for PRP showing >90% mean tumor growth inhibition versus vehicle con","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL9Rq3jF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00BQXX3D17.EUR","BK4139","LU2210149790.SGD","IE00BQXX3C00.GBP","IE00BQXX3F31.USD","IE00BN0W2V16.EUR","BCDF","IE00BGHQF748.EUR","SG9999014021.USD","IE00BN0W2T93.GBP","NDAQ","SG9999014039.USD","IE00BN0W2W23.USD","PPCB","LU2210150020.SGD","BK4588","BK4112","LU2095319765.USD","IE00BKPKM429.USD","LU0314104364.USD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4585","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662707678","title":"Propanc Biopharma - Plans Phase 1B Study in 40–45 Patients with Advanced Solid Tumors, Clinical Trial Application Expected in Coming Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2662707678","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662707678?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:30","pubTimestamp":1787833801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA2FVT49:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662707658","title":"Propanc Biopharma - Prp Reduces Metastatic Burden in Liver and Peritoneum in Preclinical Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2662707658","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662707658?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:30","pubTimestamp":1787833801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA2FVT49:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662070763","title":"Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for Prp Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit","url":"https://stock-news.laohu8.com/highlight/detail?id=2662070763","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662070763?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:30","pubTimestamp":1787833801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA2FVT49:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661261985","title":"Propanc Biopharma Issues 3.5 Million Restricted Shares to Executives, Directors, Service Providers","url":"https://stock-news.laohu8.com/highlight/detail?id=2661261985","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661261985?lang=en_us&edition=fundamental","pubTime":"2026-08-21 18:01","pubTimestamp":1787306484,"startTime":"0","endTime":"0","summary":"Propanc Biopharma issues 3.5 million restricted shares to executives, directors, service providersPropanc Biopharma board resolutions dated July 24, 2026 were executed via majority shareholder written","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL85S1XF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660608394","title":"Propanc Biopharma starts finalization of clinical trial protocol for PRP study","url":"https://stock-news.laohu8.com/highlight/detail?id=2660608394","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660608394?lang=en_us&edition=fundamental","pubTime":"2026-08-18 20:50","pubTimestamp":1787057418,"startTime":"0","endTime":"0","summary":"Propanc Biopharma (PPCB) announced it has commenced finalization of a clinical trial protocol and will conduct a feasibility assessment for its fir...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-starts-finalization-of-clinical-trial-protocol-for-prp-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-starts-finalization-of-clinical-trial-protocol-for-prp-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IDNA","PPCB","HYLG","GDOC","MEDX","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660446786","title":"Propanc Biopharma Plans First-in-Human Phase 1b Trial of PRP in up to 40 Advanced Solid Tumor Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2660446786","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660446786?lang=en_us&edition=fundamental","pubTime":"2026-08-18 20:32","pubTimestamp":1787056337,"startTime":"0","endTime":"0","summary":"Propanc Biopharma plans first-in-human Phase 1b trial of PRP in up to 40 advanced solid tumor patientsPropanc Biopharma began finalizing plans for a first-in-human Phase 1b study of PRP in up to 40 ad","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDL7Y8rDm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3D17.EUR","SG9999014005.SGD","IE00BN0W2V16.EUR","LU2210150020.SGD","SG9999014039.USD","LU2095319765.USD","BCDF","SG9999014013.SGD","LU2210149790.SGD","BK4112","IE00BN0W2T93.GBP","BK4139","BK4585","PPCB","IE00BN0W2W23.USD","IE00BGHQF748.EUR","SG9999014021.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU0314104364.USD","IE00BQXX3C00.GBP","IE00BQXX3F31.USD","BK4588","IE00B3QW5Z07.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658397776","title":"Propanc Biopharma Plans Phase 1b Study of PRP Proenzyme Therapy in Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2658397776","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658397776?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:46","pubTimestamp":1786538783,"startTime":"0","endTime":"0","summary":"Propanc Biopharma plans Phase 1b study of PRP proenzyme therapy in advanced solid tumorsPropanc outlined PRP, a once-weekly IV combination of trypsinogen and chymotrypsinogen, as a differentiation-bas","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL1QJjyz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658779079","title":"Propanc Biopharma - to File Phase 1B Clinical Trial Application for Prp in Advanced Cancer in Q4","url":"https://stock-news.laohu8.com/highlight/detail?id=2658779079","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658779079?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:36","pubTimestamp":1786538212,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4490OW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657163740","title":"Propanc reports new preclinical data for PRP in pancreatic ductal adenocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2657163740","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657163740?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:51","pubTimestamp":1786024283,"startTime":"0","endTime":"0","summary":"Propanc Biopharma (PPCB) announced new preclinical and translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma, one of th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/propanc-reports-new-preclinical-data-for-prp-in-pancreatic-ductal-adenocarcinoma-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/propanc-reports-new-preclinical-data-for-prp-in-pancreatic-ductal-adenocarcinoma-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":54,"code":"91000000","status":"200"}]}}